While transient adverse events, such as cytokine release syndrome and lymphopenia, rash have been reported, the overall safety profile appears favorable, particularly when compared with conventional immunosuppressive therapies used earlier for treatment of T1D such as azathioprine, cyclosporine and prednisone which reduce the insulin requirements and overall state of health for brief period of time but have serious hazards with long term use that voiced serious objection (14). This evidence concerns the gene INS and lymphopenia.